RxDoctor Payments DataLook up a doctor →

Charles Hodulik, MD

Psychiatry · Madison, WINPI 1770517898

Payments from drug & device makers

$15,861in general payments, 2019–2025

Across 815 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alkermes, Inc.$2K
  • Lundbeck LLC$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • plus $7K from 34 others

What the payments were for

  • Food & beverage$15,837100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,861 in reported general payments places this provider in the 95th percentile of 543 psychiatry providers in Wisconsin.

See all psychiatry providers in Wisconsin

Medicare billing

Part B allowed, 2024
$70,994
Medicare patients
97
Services billed
933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl70$110,904
CaplytaLumateperone Tosylate22$35,715
VyvanseLisdexamfetamine Dimesylate39$24,631
FanaptIloperidone12$12,622
ZyprexaOlanzapine12$12,212
Aripiprazole55$9,140
Lurasidone Hcl80$8,202
Lisdexamfetamine Dimesylate18$5,287
Methylphenidate ErMethylphenidate Hcl41$5,190
Asenapine Maleate17$4,993
BelsomraSuvorexant11$4,623
Vilazodone Hcl30$4,500
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine88$3,498
Quetiapine Fumarate146$3,372
Duloxetine Hcl98$3,065

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,809$110,90470 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$597$35,71522 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$1,122$24,63139 claims
Vanda Pharmaceuticals Inc.Fanapt$902$12,62212 claims
MerckBelsomra$57$4,62311 claims
Almatica Pharma LLCSertraline Hcl$71$90983 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 543 psychiatry providers in Wisconsin.

Other psychiatry in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →